



SUNRAY-01: A Clinical Research Trial  
in Patients With Non-Small Cell Lung  
Cancer (**NSCLC**) With a Gene Mutation  
Called **KRAS G12C**

---

● Looking for participants

## What is the Purpose of this Study?

The purpose of this study is to assess whether adding olomorasib in combination with standard-of-care anti-cancer drugs is more effective than standard of care alone in participants with untreated advanced NSCLC. NSCLC must have a specific change in the *KRAS* gene, called *KRAS* G12C.

## What is *KRAS*?

- *KRAS* is a gene that we all have. It helps our cells grow in a controlled way. In some people, the *KRAS* gene can change and stop working the right way. When this happens, cells in the body divide and can grow out of control. This can lead to lung cancer
- To check if the *KRAS* gene has changed, a doctor can perform tests using a sample of their patient's blood and/or tumor tissue

## Who Can Participate in the Study?


### People who:

- Are 18 years old or older
- Have "untreated" lung cancer with a specific change in the *KRAS* gene, called *KRAS* G12C, that is advanced and/or has spread to another part of the body
- Are well enough to walk and do light work
- Can swallow capsules

Please visit the trial website for the complete list of eligibility criteria

## What Is the Study Treatment Plan?

- All study participants will receive the standard-of-care treatment for their cancer with **olomorasib** or placebo
- **Olomorasib** is an investigational medication, which is currently being studied. It comes in capsule form, which is swallowed
- This study is double blind. This means both doctors and study participants will not know whether they will get **olomorasib** or placebo
- In this study, the investigational medicine will be given with standard-of-care lung cancer medicines in the combination:



Olomorasib will be given orally twice daily. Pembrolizumab, pemetrexed, and platinum (carboplatin or cisplatin) are given as IV infusions which will slowly drip the medicine through a tiny tube directly into the vein.

Abbreviations: IV=Intravenous; R=Randomization.

For more information, please visit the study website:



<https://trials.lilly.com/en-US/trial/433515>

Lilly Trials Support:  
[ClinicalTrials.gov@lilly.com](mailto:ClinicalTrials.gov@lilly.com)

The use of the investigational medicine is experimental. Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.

There may be multiple sites in this clinical trial. If you have further questions or interest in this clinical trial, please contact -  
Telephone: 1-877-285-4559 or  
1-317-615-4559

Email:[clinical\\_inquiry\\_hub@lilly.com](mailto:clinical_inquiry_hub@lilly.com)